Anti‑Alzheimer Agents prior authorization
Customize your policy alerts
Sign up for allcareadvantage Policy 118.2 alerts
Get alerted when Policy 118.2 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, coverage criteria, and renewal requirements for anti‑Alzheimer agents (FDA‑approved treatment of Alzheimer's disease) for AllCare Advantage members aged ≥18. Applies to coverage determinations and documentation required for approval and renewal.
No material clinical or coverage changes in this revision.
Coverage Criteria for Anti‑Alzheimer Agents
Initial approval criteria
Covered when ALL of the following are met
If all initial criteria are met, approve up to 6 months; if off-label documentation is not met, deny.
Renewal criteria
Renewal requires ALL of the following
If met, approve an additional 6 months with quantity limits; if not met, deny.
This policy applies to FDA‑approved treatments for Alzheimer's disease (AD). Off‑label indications are not specified in the policy (Off‑label indication: n/a) and will only be considered when sufficient documentation is provided to support the off‑label use. Treatment is intended for adult members and coverage is limited to indications and durations supported by published data and the clinical trial populations in which the therapies were studied.
Initiation of therapy outside the disease stages studied in the clinical trials or without documentation matching the trial population is considered not meeting criteria and will be denied. Providers must supply documentation that matches the clinical‑trial population (chart notes or attestation). Requests lacking required baseline testing — including confirmation of amyloid‑beta plaques, a baseline brain MRI within one year prior to treatment, or a qualifying cognitive assessment — should be expected to be denied.
For renewals, prior authorization remains required and approval is contingent on meeting the renewal criteria: the member must have met the initial criteria at the time of initial approval, and the request must include documentation that the patient has experienced continued clinical benefit. If renewal documentation does not demonstrate continued benefit, the request will be denied.
Clinical Thresholds and Scoring
Prior Authorization, Documentation, and Provider Requirements
Prior authorization required; approvals granted in 6‑month intervals
Prior authorization is required for anti‑Alzheimer agents; if all initial criteria are met, approve for up to 6 months initially. Renewal approvals are also for up to 6 months and require documentation that the member met the initial criteria and has experienced continued clinical benefit.
- Initial approval: Approve x6 months when all initial criteria are met.
- Renewal approval: Approve x6 months with quantity limits when renewal criteria are met (member met initial criteria and documentation of continued clinical benefit).
No step therapy required
This policy does not require step therapy prior to initiation; no step therapy requirements are specified in the document.
Required documentation to support approval
Submit documentation that confirms amyloid‑beta plaque presence and baseline testing:
- Radiology report or chart notes documenting presence of amyloid‑beta plaques.
- Baseline cognitive assessment showing CDR global score 0.5 or 1.0 OR MMSE score 22–30.
- Baseline brain MRI report dated within one year prior to treatment.
- Documentation/attestation that the patient matches the population studied in the clinical trial(s).
- When requesting off‑label use, include sufficient documentation to support the off‑label indication.
Primary triggers for denial
Requests will be denied when key coverage criteria or required documentation are not met.
- Diagnosis/staging: Patient does not have a diagnosis of mild Alzheimer's disease or mild cognitive impairment due to Alzheimer's disease = Deny.
- Cognitive thresholds: CDR global score outside 0.5–1.0 or MMSE outside 22–30 = Deny.
- Imaging: No documentation of amyloid‑beta plaque presence (radiology report/chart notes) = Deny.
- Baseline MRI: No baseline brain MRI within one year prior to treatment = Deny.
- Clinical trial match/off‑label: Lack of documentation/attestation that the patient matches the clinical trial population, or insufficient support for off‑label use = Deny.
Key Definitions and Indications
Policy Background
This policy covers FDA‑approved anti‑Alzheimer agents for adult members and emphasizes initiating treatment in patients whose characteristics and disease stage match the populations enrolled in the clinical trials that established safety and effectiveness. There are limited or no data to support initiating treatment at earlier or later disease stages than those studied; therefore, treatment should be limited to durations supported by published trial data and approved labeling.
Key baseline requirements reflect the trial populations and include documentation of amyloid‑beta plaque presence, a baseline cognitive assessment meeting MMSE 22–30 OR CDR global score 0.5 or 1.0, and a baseline brain MRI within one year prior to treatment. Coverage decisions and approval lengths follow these criteria.
Policy Revision History
Policy originated (Date of origin) and became effective on 2023-06-02.
Policy underwent review on 2024-12-19 (Date of Last Review).
Next scheduled review is 2026-12-19; also recorded as last/next review in document header.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.